About the Company
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Employees
27
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SESN News
SESEN BIO, INC. (SESN) Gains As Market Dips: What You Should Know
SESEN BIO, INC. (SESN) closed the most recent trading day at $0.56, moving +1.8% from the previous trading session. The stock outpaced the S&P 500's daily loss of 1.06%. Meanwhile, the Dow lost 0. ...
Sesen Bio wins shareholder approval for Carisma merger
Meanwhile, ~86% of votes endorsed a decision to affect a 1-for-20 reverse split of Sesen Bio shares. The approval for both proposals was required to close the merger, which is now expected to ...
Sesen Bio Stock Drops After FDA Decision, Wainwright Cut to Neutral
The shares are lower. Sesen Bio (SESN) shares dropped on Monday, extending Friday’s decline, as HC Wainwright downgraded the drugmaker after the FDA last week denied marketing clearance for ...
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”) management team on ...
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum™, also known as ...
Leslie Dan's Net Worth
Leslie Dan has an estimated net worth of $7.16 Million. This is based on reported shares in Sesen Bio, Inc..
Assembly Bio to launch four infectious disease trials in 2024
Assembly Bio has four candidates in its pipeline, one of which is being developed as part of a partnership with Gilead ...
Carisma Therapeutics Inc (CARM)
Investors in Sesen Bio, Inc. (NASDAQ:SESN) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 16, 2019 $2.50 Call had ...
PALI Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company ...
bluebird bio, Inc. (BLUE)
SOMERVILLE, Mass., March 11, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene ...
TRML Tourmaline Bio, Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human anti-IL-6 monoclonal ...
bluebird bio, Inc.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Loading the latest forecasts...